Abstract
Early clinical successes are driving enthusiasm for fecal microbiota transplantation (FMT), the transfer of healthy gut bacteria through whole stool, as emerging research is linking the microbiome to many different diseases. However, preliminary trials have yielded mixed results and suggest that heterogeneity in donor stool may play a role in patient response. Thus, clinical trials may fail because an ineffective donor was chosen rather than because FMT is not appropriate for the indication. Here, we describe a conceptual framework to guide rational donor selection to increase the likelihood that FMT clinical trials will succeed. We argue that the mechanism by which the microbiome is hypothesized to be associated with a given indication should inform how donors are selected for FMT trials, categorizing these mechanisms into four disease models and presenting associated donor selection strategies. We next walk through examples based on previously published FMT trials and ongoing investigations to illustrate how donor selection might occur in practice. Finally, we show that typical FMT trials are not powered to discover individual taxa mediating patient responses, suggesting that clinicians should develop targeted hypotheses for retrospective analyses and design their clinical trials accordingly. Moving forward, developing and applying novel clinical trial design methodologies like rational donor selection will be necessary to ensure that FMT successfully translates into clinical impact.
Competing Interest Statement
E.A. is co-founder of Finch therapeutics. C.Z, P.P, S.B, and M.O. are employed by OpenBiome.
Funding Statement
C.D. acknowledges funding from the Siebel Scholars Program.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
NA
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
NA
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: E.A. is co-founder of Finch therapeutics. C.Z, P.P, S.B, and M.O. are employed by OpenBiome.
Data Availability
Code to reproduce all of these analyses and figures can be found at https://github.com/cduvallet/donor-selection/. Data were downloaded from original sources as described in the Methods section.
